Should you buy Repligen (REP) stock?
The bioprocessing leader is having a bad day, but there doesn't appear to be any reason to panic. What happened Shares of Repligen ( RGEN -0.04% ) …
Does Repligen stock have a dividend growth track record?
Sep 09, 2019 · Shares of Repligen (NASDAQ: RGEN) lost over 13% today, although there doesn't appear to be any company-specific news dragging the stock down. This simply appears to be good old-fashioned volatility...
What are Wall Street's target prices for Repligen's stock?
Oct 13, 2021 · The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last ...
Is Repligen's acquisition spree enough to generate adequate returns for shareholders?
Apr 03, 2022 · 7 analysts have issued twelve-month target prices for Repligen's shares. Their forecasts range from $240.00 to $368.00. On average, they expect Repligen's share price to reach $306.14 in the next twelve months. This suggests a possible upside of …
Is Repligen a good stock to buy?
Repligen has received a consensus rating of Buy.
Why is RGEN falling?
Repligen (RGEN) has been beaten down lately with too much selling pressure. While the stock has lost 16.5% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Jan 10, 2022
Is Repligen overvalued?
What's the opportunity in Repligen? Repligen appears to be overvalued by 38% at the moment, based on my discounted cash flow valuation. The stock is currently priced at US$286 on the market compared to my intrinsic value of $206.75.Sep 29, 2021
What does Repligen make?
biologic drugsRepligen is a bioprocessing-focused life sciences company bringing expertise and innovation to our customers since 1981. We are inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs.
Is Repligen a good company to work for?
Excellent Community and Employee Engagment Repligen is a tight knit community of peers. Upper management is constantly engaging their employees and upholding their employee culture. Time off is very flexible and benefits are comparable to other companies. Compensation is on the low end.
Is Repligen a public company?
Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in Delaware in 1981....Repligen.TypePublic companyWebsitewww.repligen.com12 more rows
When did Repligen go public?
Dec. 07, 2020WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock at a public offering price of $181 per share.Dec 7, 2020
How big is Repligen?
Repligen's current market capitalization is $10.4 b.
How many employees does Repligen have?
Repligen total number of employees in 2020 was 1,128, a 48.23% increase from 2019. Repligen total number of employees in 2019 was 761, a 38.87% increase from 2018. Repligen total number of employees in 2018 was 548, a 15.13% increase from 2017.
Is Repligen a buy right now?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 7 buy ratings for the stock...
How has Repligen's stock been impacted by Coronavirus?
Repligen's stock was trading at $91.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Sin...
Are investors shorting Repligen?
Repligen saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 2,090,000 shares, an incre...
When is Repligen's next earnings date?
Repligen is scheduled to release its next quarterly earnings announcement on Tuesday, May 3rd 2022. View our earnings forecast for Repligen .
How were Repligen's earnings last quarter?
Repligen Co. (NASDAQ:RGEN) announced its earnings results on Thursday, February, 17th. The biotechnology company reported $0.81 earnings per share...
What guidance has Repligen issued on next quarter's earnings?
Repligen issued an update on its FY 2022 earnings guidance on Thursday, March, 10th. The company provided earnings per share (EPS) guidance of $3.2...
What price target have analysts set for RGEN?
7 equities research analysts have issued 1-year target prices for Repligen's stock. Their forecasts range from $240.00 to $368.00. On average, they...
Who are Repligen's key executives?
Repligen's management team includes the following people: Tony J. Hunt , President, Chief Executive Officer & Director James R. Bylund , Chief O...
What is Tony J. Hunt's approval rating as Repligen's CEO?
13 employees have rated Repligen CEO Tony J. Hunt on Glassdoor.com . Tony J. Hunt has an approval rating of 52% among Repligen's employees. This p...
What happened
Shares of Repligen (NASDAQ: RGEN) lost over 13% today, although there doesn't appear to be any company-specific news dragging the stock down. This simply appears to be good old-fashioned volatility caused by the stock's own success.
So what
Repligen develops bioprocess equipment and consumables that help customers safely and efficiently manufacture biologic drugs. Business is booming thanks to the global rise of biopharmaceuticals: First-half 2019 revenue soared 42% from the year-ago period to $131 million, while operating income jumped 117% to $22 million in that span.
Now what
Assuming there really isn't any devastating news driving shares lower, investors with a long-term mindset shouldn't think anything of today's drop. Repligen has been a great growth stock, as evidenced by its five-year return of 319%.
Is Repligen a buy right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Repligen stock.#N#View analyst ratings for Repligen or view top-rated stocks.
What stocks does MarketBeat like better than Repligen?
Wall Street analysts have given Repligen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Repligen wasn't one of them.
When is Repligen's next earnings date?
Repligen is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.#N#View our earnings forecast for Repligen.
How were Repligen's earnings last quarter?
Repligen Co. (NASDAQ:RGEN) issued its earnings results on Monday, July, 26th. The biotechnology company reported $0.79 EPS for the quarter, topping the Zacks' consensus estimate of $0.52 by $0.27. The biotechnology company had revenue of $162.96 million for the quarter, compared to the consensus estimate of $144.24 million.
How has Repligen's stock been impacted by COVID-19 (Coronavirus)?
Repligen's stock was trading at $91.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGEN shares have increased by 214.1% and is now trading at $285.87.#N#View which stocks have been most impacted by COVID-19.
What guidance has Repligen issued on next quarter's earnings?
Repligen issued an update on its FY 2021 earnings guidance on Tuesday, August, 3rd. The company provided earnings per share guidance of $2.710-$2.780 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.250.
What price target have analysts set for RGEN?
5 brokerages have issued 12-month price objectives for Repligen's stock. Their forecasts range from $240.00 to $290.00. On average, they anticipate Repligen's stock price to reach $259.50 in the next year.
How many shares of Rgen are underwritten?
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock at a public...
When is the next conference call for 2021?
Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT
Signals & Forecast
Mostly positive signals in the chart today. The Repligen Corporation stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Support, Risk & Stop-loss
On the downside, the stock finds support just below today's level from accumulated volume at $254.67 and $235.28. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Repligen Corporation finds support just below today's level at $254.67.
Is Repligen Corporation stock A Buy?
Several short-term signals are positive and the stock has broke the rising trend up, which indicates an even stronger rate of rising. We conclude that the current level may hold a buying opportunity as there is a fair chance for Repligen Corporation stock to perform well in the short-term period.